Loading patent…
AssigneeUniversity College Cardiff Consultants Limited
InventorsBernhard Moser, Marlene Brandes Kuchen
Estimating the term…
The invention relates to a method for the preparation of efficient antigen-presenting human γδ T cells, to the γδ T cells prepared by such a method, and to their use in immunotherapy, vaccination, vaccine development and diagnostics. Similar to dendritic cells (DCs) in potency and efficacy, these human γδ T cells process antigens and present antigenic peptides to αβ T cells and induce antigen-specific responses (proliferation and differentiation) in naïve αβ T cells. γδ T cells are easily purified from peripheral blood, acquire “maturation” status (expression of essential adhesion, co-stimulatory and major histocompatibility complex molecules) within 1 day of in vitro culture under stimulation and induce strong primary and secondary T helper cell and cytotoxic T cell responses. The γδ T cells may be used in a method of treatment of tumors or chronic or recurrent infectious diseases, in identification of novel tumor or pathogen-derived antigens, and in the diagnosis of the immune competence of a patient.
A method for the preparation of efficient antigen-presenting human γδ T cells comprising selecting γδ T cells out of human peripheral blood mononuclear cells, treating the selected cells with a stimulus for induction of antigen-presenting functions, and applying the antigen for uptake and presentation by these cells.
Use of efficient antigen-presenting human γδ T cells in immunotherapy.
Use of efficient antigen-presenting human γδ T cells for the manufacture of a medicament for use in immunotherapy or vaccination.
A method of treatment of tumors or chronic or recurrent infectious diseases wherein efficient antigen-presenting human γδ T cells are injected into a patient in need thereof.
A method of vaccination against tumors or agents inducing chronic or recurrent infectious diseases wherein efficient antigen-presenting human γδ T cells, to which non-infectious and non-tumorigenic antigens for uptake and presentation have been applied, are injected into a patient to be vaccinated.
Use of γδ T cell-targeting vaccines for the manufacture of a medicament for use in immunotherapy or vaccination.
A method of vaccination against tumors or agents inducing infectious or non-infectious diseases wherein γδ T cell-targeting vaccines are administered to a patient to be vaccinated.
A method of identification of novel tumor-associated or pathogen-derived antigens comprising selecting γδ T cells out of human peripheral blood mononuclear cells, treating the selected cells with a stimulus for induction of antigen-presenting functions, applying fractions of an undefined protein mixture, or crude or enriched extracts from tumor and infected cells, or RNA or DNA libraries derived from tumors and infectious agents, testing for in vitro activation of autologous naïve αβ T cells, and selecting protein samples with increased antigenicity.
A method of diagnosing the immune competence of a patient comprising selecting γδ T cells out of the patient's peripheral blood mononuclear cells, treating the selected cells with a stimulus for induction of antigen-presenting functions, applying the antigen for which the immune competence has to be determined, and testing for in vitro activation of autologous αβ T cells.
Dependencies are inferred from the claim text.